share_log

Pfizer | 4: Statement of changes in beneficial ownership of securities-Officer BOURLA ALBERT

Pfizer | 4: Statement of changes in beneficial ownership of securities-Officer BOURLA ALBERT

輝瑞 | 4:持股變動聲明-高管 BOURLA ALBERT
美股sec公告 ·  06/17 21:45
Moomoo AI 已提取核心訊息
Pfizer Inc. (PFE) Chairman & CEO Albert Bourla executed a transaction on June 14, 2024. The specific details of the transaction, including the number of shares involved and the transaction price, were not disclosed in the announcement. As the head of the pharmaceutical giant, Bourla's financial moves are closely watched by investors for indications of his confidence in the company's performance and prospects. The absence of detailed transaction data in the report leaves the impact of this event on Pfizer's stock somewhat unclear to shareholders and potential investors.
Pfizer Inc. (PFE) Chairman & CEO Albert Bourla executed a transaction on June 14, 2024. The specific details of the transaction, including the number of shares involved and the transaction price, were not disclosed in the announcement. As the head of the pharmaceutical giant, Bourla's financial moves are closely watched by investors for indications of his confidence in the company's performance and prospects. The absence of detailed transaction data in the report leaves the impact of this event on Pfizer's stock somewhat unclear to shareholders and potential investors.
輝瑞公司(PFE)董事長兼首席執行官阿爾伯特·布爾拉於2024年6月14日執行了一項交易。公告中沒有透露交易涉及的股份數量和交易價格的具體細節。作爲這家藥品巨頭的負責人,布爾拉的財務舉動受到投資者的密切關注,以判斷他對公司業績和前景的信懇智能。報告中未提供詳細的交易數據,使得這一事件對輝瑞股票的影響對股東和潛在投資者而言有些不明確。
輝瑞公司(PFE)董事長兼首席執行官阿爾伯特·布爾拉於2024年6月14日執行了一項交易。公告中沒有透露交易涉及的股份數量和交易價格的具體細節。作爲這家藥品巨頭的負責人,布爾拉的財務舉動受到投資者的密切關注,以判斷他對公司業績和前景的信懇智能。報告中未提供詳細的交易數據,使得這一事件對輝瑞股票的影響對股東和潛在投資者而言有些不明確。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息